PCT/GB2004/002499

A. CLASSIFICATION OF SUBJECT NATTER IPC 7 A61K39/12 A61K A61K39/04 A61P31/00 A61K39/39 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 **A61K** Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category ° WO 00/00216 A (SAMBHARA SURYAPRAKASH 1-57 X PASTEUR MERIEUX SERUMS VACC (FR); MOSTE CATHER) 6 January 2000 (2000-01-06) the whole document X WO 01/30989 A (RENNER WOLFGANG A; NIEBA 1-57 LARS (CH); CYTOS BIOTECHNOLOGY AG (CH)) 3 May 2001 (2001-05-03) page 46, line 24 - page 54, line 10; claims 1-87; examples 4-7 WO 96/40241 A (VIROGENETICS CORP) 1-4.8-57 X 19 December 1996 (1996-12-19) abstract: claims 1-27 Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is clied to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an invention the countries step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "O" document referring to an oral disclosure, use, exhibition or document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the International search report 26/10/2004 19 October 2004 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patenthaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Hermann, P Fax: (+31-70) 340-3016

PCT/GB2004/002499

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *		Relevant to claim No.
	KENT STEPHEN J ET AL: "Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 12, December 1998 (1998-12), pages 10180-10188, XP002179215 ISSN: 0022-538X the whole document	1-57
A	SCHNEIDER J ET AL: "ENHANCED IMMUNOGENICITY FOR CD8+ T CELL INDUCTION AND COMPLETE PROTECTIVE EFFICACY OF MALARIA DNA VACCINATION BY BOOSTING WITH MODIEFIED VACCINIA VIRUS ANKARA" NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 4, April 1998 (1998-04), pages 397-402, XP000739989 ISSN: 1078-8956 the whole document	1-57
A	US 2002/032162 A1 (HUYGEN KRIS ET AL) 14 March 2002 (2002-03-14) the whole document	1-57
A	WO 01/38358 A (CHIRON CORP; GLAZER EDWARD (US); SELBY MARK (US); HOUGHTON MICHAEL (U) 31 May 2001 (2001-05-31) the whole document	1-57

PCT/GB2004/002499

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)
This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 38, 39, and 42-57 are directed to a method of treatment of the human/animal body contrary to the requirements of Rule 39.1(iv) PCT, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This international Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

information on patent family members

PCT/GB2004/002499

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0000216	A	06-01-2000	AU	5036899 A	
			CA	2335508 A	
			WO	0000216 A	
			EP	1087789 A	
			US	6641816 B	1 04-11-2003
WO 0130989	Α	03-05-2001	AU	7938900 A	08-05-2001
			EP	1226238 A	2 31-07-2002
			WO	0130989 A	2 03-05-2001
WO 9640241	Α	19-12-1996	US	5843456 A	01-12-1998
	- '		AU	711472 B	
			AU	6314996 A	
			CA	. 2223416 A	
		•	EP	0835133 A	
			WO	9640241 A	
			JP	2000500115 T	•
US 2002032162	A1	14-03-2002	US	5736524 A	07-04-1998
00 2002	•		AU	715067 B	
			AU	4110296 A	
			CA	2205175 A	
			CN	1171814 A	
			CZ	9701451 A	
			ĔΡ	0792358 A	
			FΙ	972034 A	
			НŪ	77028 A	
			JP	10508753 T	
			NO	972196 A	
			NZ	296477 A	
			PL	320091 A	
			RÜ	2186109 0	
			SK	59797 A	
			MO 2V	9615241 A	
			ZA	9515241 A 9509608 A	
WO 0138358	Α	31-05-2001	ΑU	1928201 A	
			CA	2392527 A	
			EP	1233783 A	
			· JP	2003514576 1	
			. MO	0138358 A	
		•	US	2004146529 A	29-07-2004
					31 25-05-2004

;**-**;